These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8620409)

  • 21. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.
    Raderer M; Kornek GV; Hejna MH; Weinlaender G; Vorbeck F; Fiebiger WC; Scheithauer W
    Ann Oncol; 1997 Aug; 8(8):797-9. PubMed ID: 9332689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
    Lauria R; Ferrari E; Tramontana S; Morabito A; Perrone F; Maffeo A; Fiorentino R; Casella G; Iodice F; Ricchi P; Carlomagno C; Varriale E; De Placido G; De Placido S; Bianco AR; Pignata S
    Oncology; 1999; 56(4):267-73. PubMed ID: 10343189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
    Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
    Pignata S; Varriale E; Casella G; Iodice F; De Placido G; Perrone F; Tramontana F; Ricchi P; De Vivo R; Costanzo R; Vernaglia A; Tramontana S
    Ann Oncol; 2000 May; 11(5):613-6. PubMed ID: 10907958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
    Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.
    Frustaci S; Buonadonna A; Galligioni E; Favaro D; De Paoli A; Lo Re G; Sorio R; Tumolo S; Monfardini S
    J Clin Oncol; 1997 Apr; 15(4):1418-26. PubMed ID: 9193334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
    J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.
    Gridelli C; De Placido S; Pepe R; Incoronato P; Airoma G; Rossi A; Palazzolo G; Bianco AR
    Eur J Cancer; 1993; 29A(12):1729-31. PubMed ID: 7691117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
    J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
    Moore DF; Pazdur R
    Am J Clin Oncol; 1992 Dec; 15(6):464-6. PubMed ID: 1449107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach.
    Kornek G; Schulz F; Depisch D; Rosen H; Kwasny W; Sebesta C; Scheithauer W
    Cancer; 1993 Apr; 71(7):2177-80. PubMed ID: 8453539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
    O'Reilly SE; Gelmon KA; Onetto N; Parente J; Rubinger M; Page RA; Plenderleith IH
    J Clin Oncol; 1993 Dec; 11(12):2411-6. PubMed ID: 8246030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.